Regentis Biomaterials Advances European Commercial Launch of GelrinC with Surgeon Training Program

Regentis Biomaterials Ltd. (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.

The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.

According to Regentis, GelrinC addresses a significant unmet need in knee cartilage repair. The company estimates that approximately 470,000 cases of cartilage knee repair occur annually in the U.S. alone, where no off-the-shelf treatment is available. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.

The announcement comes as Regentis focuses on bringing its regenerative medicine technology to market. The company’s Gelrin platform is based on synchronized, degradable hydrogel implants designed to regenerate damaged or diseased tissue, including inflamed cartilage and bone. By initiating surgeon training, Regentis aims to build familiarity and confidence among orthopedic surgeons, which could drive adoption in Europe and potentially pave the way for future market expansion.

While the training program is set to begin in Italy, the company plans to expand sessions across Europe, leveraging a network of Centers of Excellence to provide ongoing education and support. This strategy aligns with Regentis’ broader goal of establishing GelrinC as a standard treatment option for knee cartilage lesions.

For more information, visit the company’s newsroom at https://ibn.fm/RGNT or the full press release at https://ibn.fm/QOWWK.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Regentis Biomaterials Advances European Commercial Launch of GelrinC with Surgeon Training Program.

The post Regentis Biomaterials Advances European Commercial Launch of GelrinC with Surgeon Training Program appeared first on citybuzz.